Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen(196170) Approves Delisting from KOSDAQ and Relisting on KOSPI at Extraordinary Shareholders’ Meeting

Posted on December 8, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen(196170) Approves Delisting from KOSDAQ and Relisting on KOSPI at Extraordinary Shareholders’ Meeting

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-12-08

Disclosure Type: Results of Extraordinary General Meeting of Shareholders

💡 3-Second Summary

Alteogen held an extraordinary general meeting of shareholders and officially approved the agenda to delist from the KOSDAQ market and transfer its listing to the KOSPI market.

📊 1. [Key Disclosure Content & Summary of Major Figures]

This disclosure outlines the voting results from the extraordinary general meeting of shareholders submitted to the regulatory authorities.

  • Date of Shareholders’ Meeting: December 08, 2025
  • Agenda Item 1: Conditional Delisting from the KOSDAQ Market and Approval of Transfer Listing to the KOSPI Market
    • Result: Approved as originally proposed
  • Agenda Item 2: Change in the Remuneration Limit for Directors
    • Result: Approved as originally proposed
  • Related Prior Disclosures: Resolution on convening an extraordinary general meeting (2025-11-06), Notice of convening a general meeting and reference documents (2025-11-21)

📈 2. [Expert View: What This Disclosure Means for Investors]

  • Approved Agendas & Contents: The item regarding the conditional delisting from the KOSDAQ market and the approval of the transfer listing to the KOSPI market was approved as originally proposed. The agenda concerning the change in the remuneration limit for directors was also approved as originally proposed.
  • Omitted Information in Disclosure: This results filing does not specify the upcoming screening schedule by the Korea Exchange, the expected date of the transfer listing, or the detailed numerical figures regarding the change in the directors’ remuneration limit.
  • Investor Interpretation: With shareholder approval secured, the internal corporate procedures required for the transfer listing have been fulfilled. However, because the actual migration to the KOSPI market is contingent upon the subsequent preliminary listing review and approval by the Korea Exchange, the final transfer timeframe must be verified through future progress updates.

📝 Editor’s Comment (by K-STOCK Editor)

The conditional delisting from the KOSDAQ market and approval of transfer listing to the KOSPI market was approved as originally proposed. The change in the remuneration limit for directors was also approved as originally proposed. The specific review timeline for the transfer listing and the exact numerical limits for director compensation are not specified within this official disclosure. While internal approval has been completed, the final migration to the main board requires passing the Korea Exchange’s preliminary review, meaning that the final execution date must be confirmed via subsequent disclosures. This commentary outlines objective metrics and does not constitute any buy or sell signals.

📢 Disclaimer & Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Alteogen(196170) Designated as Short Selling Overheated Stock… Short Selling Banned on Dec 8
Next Post: [Disclosure] SK Hynix (000660) Receives ‘Investment Warning Stock’ Advance Notice Due to Massive Year-over-Year Gain

Related Posts

[Disclosure] Alteogen (196170) to List 40,820 Additional Common Shares Following Executive Stock Option Exercises Disclosures
[Disclosure] Alteogen(196170) Resolves to Submit Agenda for Conditional KOSDAQ Delisting and KOSPI Transfer to Shareholders’ Meeting Disclosures
[Disclosure] Alteogen(196170) Signs Exclusive License Agreement with GSK Subsidiary for ALT-B4 Valued up to KRW 420.0B Disclosures
[Disclosure] Alteogen (196170) Decides to Table Agenda for Delisting Approval to Relist on KOSPI Market Disclosures
[Disclosure] Alteogen(196170) Designated as Short Selling Overheated Stock… Short Selling Banned on Dec 8 Disclosures
[Disclosure] Alteogen (196170) Reports Q1 2026 Operating Profit of KRW 39.3B… An Explosive 100% QoQ Surge Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme